| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/05/2013 | US8389713 Polysaccharide pseudo-sponge |
| 03/05/2013 | US8389700 Agent delivery system capable of selectively releasing an agent |
| 03/05/2013 | US8389687 Polyvinylpyrrolidone cryoprecipitate extraction of clotting factors |
| 03/05/2013 | US8389542 Dosage unit comprising a prostaglandin analog for treating constipation |
| 03/05/2013 | US8389502 Stabilized steroid composition and method for its preparation |
| 03/05/2013 | US8389499 Cyclodextrin-based polymers for therapeutics delivery |
| 03/05/2013 | US8389497 Using of alkylphosphocholines for the manufacture of a drug product for the therapy of benign and malignant oncoses |
| 03/05/2013 | US8389495 Olioodeoxynucleotide and its use to induce an immune response |
| 03/05/2013 | US8389470 Methods and compositions for delivering peptides |
| 03/05/2013 | US8389467 In situ self-setting mineral-polymer hybrid materials, composition and use thereof |
| 03/05/2013 | US8389011 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 03/05/2013 | US8389006 Pharmaceutical compositions of adsorbates of amorphous drug |
| 03/05/2013 | US8389001 Precursor composition for crosslinkable pressure-sensitive adhesive for skin |
| 03/05/2013 | US8388997 Method of preparing an unsaturated fatty acid dry concentrate |
| 03/05/2013 | US8388983 Film coatings containing fine particle size detackifiers and substrates coated therewith |
| 03/05/2013 | US8388977 Diagnosis of macrophage mediated disease |
| 03/05/2013 | US8388976 Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor |
| 03/05/2013 | US8388962 Molecules and methods of using same for treating MCP-1/CCR2 associated diseases |
| 03/05/2013 | US8388944 Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions |
| 03/05/2013 | US8388933 Multimeric protein toxins to target cells having multiple identifying characteristics |
| 03/05/2013 | US8387612 Self-contained heating unit and drug-supply unit employing same |
| 03/05/2013 | CA2578250C Therapeutic composition with a botulinum neurotoxin |
| 03/05/2013 | CA2545034C Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 03/05/2013 | CA2335340C Fsh and fsh variant formulations, products and methods |
| 02/28/2013 | WO2013028624A1 Compositions, devices, and methods for treating infections |
| 02/28/2013 | WO2013028032A1 Preparation for percutaneous absorption and method for preparing same |
| 02/28/2013 | WO2013027840A1 Hydrous adhesive skin patch |
| 02/28/2013 | WO2013027681A1 Transdermal patch |
| 02/28/2013 | WO2013027052A1 A device for the transdermal delivery of alkaline compounds that are susceptible to degradation in their free base form |
| 02/28/2013 | WO2013026694A1 Pharmaceutical compositions comprising voriconazole |
| 02/28/2013 | WO2013026487A1 Rigid moulded body for treating pruritus |
| 02/28/2013 | WO2013026268A1 Tumor chemotherapeutic drug formulation and preparation method thereof |
| 02/28/2013 | WO2012176212A4 Carrier based nanogel formulation for skin targeting. |
| 02/28/2013 | WO2012151247A3 FORMULATION FOR ANTI-α4β7 ANTIBODY |
| 02/28/2013 | WO2012138988A3 Organometallic anti-cancer complexes |
| 02/28/2013 | WO2012138532A3 Process for producing cellulose derivatives of high bulk density and good flowability |
| 02/28/2013 | WO2007025388A9 Anti-apoptotic protein antibodies |
| 02/28/2013 | US20130053618 Radiation sensitive liposomes |
| 02/28/2013 | US20130053514 Method Involving 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol) |
| 02/28/2013 | US20130053454 Process for the production of a composition comprising fibrillated cellulose and a composition |
| 02/28/2013 | US20130053374 Ophthalmic composition |
| 02/28/2013 | US20130053360 Controlled release and taste masking oral pharmaceutical composition |
| 02/28/2013 | US20130053324 Novel self-assembling peptides and their use in the formation of hydrogels |
| 02/28/2013 | US20130053315 Novel glp-1 derivatives |
| 02/28/2013 | US20130052737 Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 02/28/2013 | US20130052677 PEG-Urate Oxidase Conjugates and Use Thereof |
| 02/28/2013 | US20130052263 Pharmaceutical compositions with synchronized solubilizer release |
| 02/28/2013 | US20130052237 Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations |
| 02/28/2013 | US20130052218 Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions |
| 02/28/2013 | US20130052175 Oil suspension-based molded food products |
| 02/28/2013 | US20130052154 Compositions and Methods for the Treatment of Lung Inflammation |
| 02/28/2013 | US20130052142 Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 02/28/2013 | US20130052135 Molecules With Extended Half-Lives, Compositions And Uses Thereof |
| 02/28/2013 | US20130052134 Peg-plga-pll polymer and method for preparing and using the same as the drug and gene carrier |
| 02/28/2013 | DE4396086B3 Sirup mit N-Acetylcystein Syrup with N-acetylcysteine |
| 02/28/2013 | CA2846121A1 Hydrous adhesive skin patch |
| 02/28/2013 | CA2846092A1 Peg-interferon lambda 1 conjugates |
| 02/28/2013 | CA2844785A1 Dermal filler compositions including antioxidants |
| 02/27/2013 | EP2562212A1 Hydrogel |
| 02/27/2013 | EP2561892A1 Easily dosable solid preparation |
| 02/27/2013 | EP2561891A2 Means and methods of enhancing delivery to biological systems |
| 02/27/2013 | EP2561888A1 Protein comprising NC-1 for treating angiogenesis-related diseases |
| 02/27/2013 | EP2561878A1 Calcium preparation and production method therefor |
| 02/27/2013 | EP2561863A1 Pharmaceutical compositions comprising voriconazole |
| 02/27/2013 | EP2561862A1 Vesicle-containing composition |
| 02/27/2013 | EP2561860A1 Implantable polymeric device for sustained release of buprenorphine |
| 02/27/2013 | EP2561070A1 New stabilizing agent for pharmaceutical proteins |
| 02/27/2013 | EP2560732A2 A solid pharmaceutical composition for neutralizing stomach acid |
| 02/27/2013 | EP2560689A1 Novel self-assembling peptides and their use in the formation of hydrogels |
| 02/27/2013 | EP2560688A1 Combination of drugs with protein-binding prodrugs |
| 02/27/2013 | EP2560687A2 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| 02/27/2013 | EP2560686A2 Selective modification of proteins |
| 02/27/2013 | EP2560666A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate) |
| 02/27/2013 | EP2560665A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates |
| 02/27/2013 | EP2560645A2 Novel conjugates of cc-1065 analogs and bifunctional linkers |
| 02/27/2013 | EP2560633A2 Intravenous omega-3 fatty acid compositions & method of use |
| 02/27/2013 | EP2560626A1 Local anesthetic emulsion compositions and methods of making and using the same |
| 02/27/2013 | EP2560618A1 Melt-granulated fingolimod |
| 02/27/2013 | EP2560614A1 Pharmaceutical compositions and methods for administering the same |
| 02/27/2013 | EP2560610A1 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram |
| 02/27/2013 | EP2560605A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates) |
| 02/27/2013 | EP2560486A1 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| 02/27/2013 | EP2560484A1 A pharmaceutical composition of nanoparticles |
| 02/27/2013 | EP2545940A9 Parenteral compositions |
| 02/27/2013 | CN102946903A High concentration antibody formulations |
| 02/27/2013 | CN102946889A Calcium preparation and production method therefor |
| 02/27/2013 | CN102946883A Method and ophthalmic composition for treating retinal disease |
| 02/27/2013 | CN102946867A Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
| 02/27/2013 | CN102946863A Long-term storage of non-glycosylated recombinant human G-CSF |
| 02/27/2013 | CN102946862A Topical pharmaceutical composition comprising heparin |
| 02/27/2013 | CN102946861A Concentrated protein formulations and uses thereof |
| 02/27/2013 | CN102946856A Oral film formulation |
| 02/27/2013 | CN102946855A Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 02/27/2013 | CN102943067A Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 02/27/2013 | CN102942695A Polymer, glucose nano gel, glucose nano gel composition and preparation method thereof |
| 02/27/2013 | CN102942660A Natural biological crosslinking nanocomposite three-dimensional gel bracket and preparation method |
| 02/27/2013 | CN102942616A Peptide capable of binding to immunoglobulin |
| 02/27/2013 | CN102941043A Method of preparing porous polymer microspheres by high voltage electrostatic anti-solvent process |
| 02/27/2013 | CN102940892A Preparation method of targeting porphyrin fluorescent molecule and gold nanorod dyad |
| 02/27/2013 | CN102940891A Lipids, lipid complexes and use thereof |